SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024

SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024

SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024

SOHM, Inc. Further Advances its Work in the Field of Genome Editing and ABBIE, a Retroviral Integrase with Linked Guided DNA Binding Domain

CHINO HILLS, Calif., May 22, 2024 (GLOBE NEWSWIRE) — via IBN — SOHM, Inc. (OTC PINK: SHMN)– a leading generic pharmaceutical and upstart biotechnology company, is proud to announce its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This groundbreaking technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells.

The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents.

The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in Q3. This has been possible due to our committed, consistent and focused approach by our lead scientists at our lab at UACI in Tucson, AZ.

The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.

“We are excited about the potential of ABBIE to transform the field of genome editing and are committed to continuing our research to unlock its full capabilities,” said David Aguilar, COO of SOHM, Inc. “We believe that ABBIE has the potential to revolutionize genetic engineering and have a lasting impact on the future of medicine and biotechnology.”

For more information about SOHM Inc. and its work on ABBIE, please visit

About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.

To learn more about SOHM, Inc., visit

SOHM, Inc.:
Name: Dr. David Aguilar, COO
Phone: (714) 522-6700

Safe Harbor Statement:
This news release contains “forward-looking statements,” which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on

Wire Service Contact:
Los Angeles, California
310.299.1717 Office